Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Complicanze correlate all'EXTUBE: lo studio EXTUBE (EXTUBE) (EXTUBE)

19 ottobre 2026 aggiornato da: University Health Network, Toronto

Complicazioni correlate all'EXtubazione: uno studio osservazionale internazionale per comprenderne l'impatto e le migliori pratiche in sala operatoria e nell'unità di terapia intensiva: lo studio EXTUBE

EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general anesthesia or after critical illness in the operating room (OR), out of OR anesthesia location or intensive care unit (ICU).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Globally, over 200 million people each year require extubation. While routinely performed, extubation is a skilled and potentially high-risk procedure that should be performed only when physiologic, pharmacologic, and contextual conditions are optimal. Complications at this stage of patient care can result in decreased oxygen delivery to the brain and body, sometimes leading to serious adverse events such as cardiac arrest, brain damage, or death. Indeed, one quarter of airway complications that result in death or brain death occur at the time of extubation.

Despite the frequency of extubation and the potential for life-threatening complications, there is a lack of systematic data on the rate and circumstances under which these severe complications occur. The limited data indicate 10-30% of extubations may lead to severe complications, depending on the population and outcome definition. However, the certainty of these estimates is severely limited because they are based on studies that are small, mostly single-center, based on clinician recall, only capture a small portion of extubation complications (e.g., malpractice claims), or do not reflect current clinical practice. In addition, most lack a denominator and exclude successful extubations, making estimates of actual complication rates and risk factors impossible.

There has been no large study of extubation techniques or adherence to guidelines, so procedural factors associated with complications must be elucidated. While adherence to clinical practice guidelines has not been formally evaluated, surveys show non-adherence to some best practices and considerable variation in practice, and data from audits and medicolegal claims show that lack of adherence to best practices is frequently at the root cause of severe adverse extubation outcomes, with half of the complications deemed preventable. Therefore, data on the frequency and nature of extubation complications, patient and procedural risk factors for complications, and guideline adherence rates are needed before these preventable events can be addressed.

EXTUBE (EXtubation related complications - an international observational study To Understand the impact and BEst practices in the operating room and intensive care unit) is an international, multicenter, prospective cohort study

The primary objective of this study is to estimate the incidence of immediate complications related to extubation in adult patients after general anesthesia and/or after critical illness. The secondary objectives are to determine: 1) the incidence of mild extubation complications; 2) patient- and procedure-related risk factors for extubation complications; 3) the association between extubation complications and outcomes until hospital discharge; and 4) the rate of adherence to extubation clinical practice guidelines.

Tipo di studio

Osservativo

Iscrizione (Stimato)

3000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Shayan Wasim, MPH, BSc
  • Numero di telefono: 4221 +1 416 340 4800
  • Email: shayan.wasim@uhn.ca

Luoghi di studio

    • New South Wales
      • Sydney, New South Wales, Australia, 2065
        • Completato
        • Royal North Shore Hospital
    • Victoria
      • Melbourne, Victoria, Australia, 3135
        • Completato
        • Eastern Health - Maroondah Hospital
      • Melbourne, Victoria, Australia, 3156
        • Completato
        • Eastern Health - Angliss Hospital
      • Melbourne, Victoria, Australia, 3076
        • Completato
        • The Northern Hospital
      • Melbourne, Victoria, Australia, 3128
        • Completato
        • Eastern Health - Box Hill Hospital
      • Melbourne, Victoria, Australia, 3084
        • Completato
        • Austin Health - Austin Hospital
      • Melbourne, Victoria, Australia, 3079
        • Completato
        • Austin Health - Heidelberg Repatriation Hospital
    • British Columbia
      • Surrey, British Columbia, Canada, V3V 1Z2
        • Completato
        • Surrey Memorial Hospital
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 4B7
        • Completato
        • The Moncton Hospital
    • Ontario
      • North York, Ontario, Canada, M4N 3M5
        • Completato
        • Sunnybrook Hospital
      • Saint Catharines, Ontario, Canada, L2S 0A9
        • Completato
        • Niagara Health - Marotta Family Hospital
      • Toronto, Ontario, Canada, M5B 1W8
        • Completato
        • St. Michael's Hospital
      • Toronto, Ontario, Canada, M5G 1X5
        • Completato
        • Mount Sinai Hospital
      • Toronto, Ontario, Canada, M5G 2C4
        • Reclutamento
        • University Health Network - Toronto General Hospital
        • Contatto:
        • Investigatore principale:
          • Matteo Parotto, MD, PhD
        • Contatto:
        • Sub-investigatore:
          • Alicia Grassi, MD
      • Toronto, Ontario, Canada, M5T 2S8
        • Completato
        • University Health Network - Toronto Western Hospital
    • Quebec
      • Montreal, Quebec, Canada, H2X 0C1
        • Completato
        • Centre hospitalier de l'Université de Montréal (CHUM)
      • Piedecuesta, Colombia
        • Completato
        • Hospital Internacional de Colombia
      • Castlebar, Irlanda, F23 H529
        • Completato
        • Mayo University Hospital
      • Cork, Irlanda, T12 DFK4
        • Completato
        • Cork University Hospital
      • Dublin, Irlanda, D07 R2WY
        • Completato
        • Mater Misericordiae University Hospital
      • Galway, Irlanda, H91 YR71
        • Completato
        • Galway University Hospitals
      • Waterford, Irlanda, X91 ER8E
        • Non ancora reclutamento
        • University Hospital Waterford
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Dulmi T Nawarathna, MBBS, MCAI, FCAI
        • Sub-investigatore:
          • Sheeba Hakak, MBBS, FCARCSI, EDIC, HCM.
      • Kuwait City, Kuwait
        • Completato
        • Amiri Hospital
      • Auckland, Nuova Zelanda, 1023
        • Completato
        • Auckland City Hospital
      • Invercargill, Nuova Zelanda, 9812
        • Completato
        • Southland Hospital
      • Rotorua, Nuova Zelanda, 3010
        • Completato
        • Rotorua Hospital
      • Bath, Regno Unito, BA1 3NG
        • Completato
        • Royal United Hospitals Bath
      • Newcastle upon Tyne, Regno Unito, NE7 7DN
        • Completato
        • Freeman Hospital
      • Singapore, Singapore, 308433
        • Completato
        • Tan Tock Seng Hospital
    • Arizona
      • Tucson, Arizona, Stati Uniti, 85724-5114
        • Completato
        • Banner University Medical Centre
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Completato
        • University of Arkansas for Medical Sciences
    • Florida
      • Gainesville, Florida, Stati Uniti, 32608
        • Completato
        • University of Florida
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Completato
        • The University of Chicago
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Completato
        • Oregon Health & Science University
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Completato
        • The University of Texas Health Science Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

All adult patients (≥18 years old) undergoing extubation of an endotracheal tube (including index extubation and re-extubations) after general anesthesia in the OR, out of OR anesthesia location or ICU during the specified enrollment window (up to 4 weeks).

Descrizione

Inclusion Criteria:

  • Adult patients (≥18 years old)
  • Undergoing extubation of an endotracheal tube (including index extubation and re-extubations) after general anesthesia in the OR, out of OR anesthesia location or ICU
  • Undergoing extubation during the specified enrollment window

Exclusion Criteria:

  • Patients will be excluded if the extubation is performed in the context of withdrawal of life support measures,
  • Patients will be excluded if the extubation is performed for tracheostomy decannulation

For each patient who is not included, reasons for exclusion will be reported.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
At least one of the following, occurring within 60minutes after extubation (composite outcome): i) Severe hypoxemia ii) Cardiac arrest iii) Need for airway management
Lasso di tempo: Within 60 minutes after the end of extubation

The primary outcome will be the occurrence of at least one of the following (composite outcome) occurring within 60 minutes after the end of extubation:

i) Severe hypoxemia (oxygen saturation as measured by pulse oximetry falls below SpO2 < 80% for > 5 minutes) ii) Cardiac arrest iii) Need for airway management (reintubation, insertion of a supraglottic airway, bag-mask ventilation).

Within 60 minutes after the end of extubation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Difficult airway and complications related to airway management if reintubation is required
Lasso di tempo: Within 60 minutes after the end of extubation

Difficult airway (i.e., experienced difficulty by an experienced airway manager with any or all of laryngoscopy or tracheal intubation, supraglottic airway use, face-mask ventilation, or front-of-neck airway) and complications related to airway management (e.g., esophageal intubation) if reintubation is required

Within 60 minutes after the end of extubation
Planned and unplanned non-invasive respiratory support
Lasso di tempo: Within 60 minutes after the end of extubation

Planned and unplanned non-invasive respiratory support or high flow nasal cannula

Within 60 minutes after the end of extubation
Emergency front of neck airway
Lasso di tempo: Within 60 minutes after the end of extubation

Emergency front of neck airway should airway management be required after extubation

Within 60 minutes after the end of extubation
Cardiac arrhythmia requiring chemical or electrical treatment
Lasso di tempo: Within 60 minutes after the end of extubation

Cardiac arrhythmia requiring chemical or electrical treatment

Within 60 minutes after the end of extubation
Severe Hypotension
Lasso di tempo: Within 60 minutes after the end of extubation

Severe hypotension (systolic arterial pressure < 65 mmHg recorded at any time or systolic arterial pressure < 90 mmHg for > 30 minutes or new need/increase of vasopressor and/or fluid load > 15 mL/kg)

Within 60 minutes after the end of extubation
Severe Hypertension
Lasso di tempo: Within 60 minutes after the end of extubation

Severe hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg),

Within 60 minutes after the end of extubation
Pulmonary aspiration
Lasso di tempo: Within 60 minutes after the end of extubation

Aspiration of gastric contents (gastric contents inhaled into the larynx and the respiratory tract)

Within 60 minutes after the end of extubation
Barotrauma
Lasso di tempo: Within 60 minutes after the end of extubation

Pneumothorax/pneumo-mediastinum

Within 60 minutes after the end of extubation
Dental injury
Lasso di tempo: Within 60 minutes after the end of extubation

Dental injury (notable change to the patient's dentition attributable to extubation or to reintubation, should this be required)

Within 60 minutes after the end of extubation
Airways injury
Lasso di tempo: Within 60 minutes after the end of extubation

Airways injury (e.g., vocal cord damage, arytenoid dislocation

Within 60 minutes after the end of extubation
Mortality
Lasso di tempo: Within 7 days after extubation

In-hospital mortality

Within 7 days after extubation
Re-intubation
Lasso di tempo: Within 48 hours after extubation

Re-intubation within 48 hours of extubation

Within 48 hours after extubation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Matteo Parotto, MD, PhD, UHN

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 aprile 2025

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

28 marzo 2024

Primo inviato che soddisfa i criteri di controllo qualità

3 giugno 2024

Primo Inserito (Effettivo)

5 giugno 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 ottobre 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 24-5811
  • 4850 (Altro identificatore: Clinical Trials Ontario - CTO)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi